ImmuPharma (LON:IMM) Trading Down 11.3% - Here's Why

Key Points

• ImmuPharma plc shares fell by 11.3%, trading as low as GBX 10.51 ($0.14) amid a significant increase in trading volume of 9.6 million shares.
• The company reported negative earnings per share of GBX (0.38) for the last quarter and is forecasted to post an even larger negative EPS for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program being Lupuzor™, aimed at treating Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded down 11.3% during trading on Monday . The company traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.09 ($0.15). 9,637,198 shares were traded during trading, an increase of 13% from the average session volume of 8,505,251 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Price Performance

The stock's 50-day simple moving average is GBX 4.28 and its 200 day simple moving average is GBX 3.27. The stock has a market capitalization of £56.23 million, a P/E ratio of -1,264.38 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.